Compare Progressive Corp (PGR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Twist Bioscience Corp — how do they compare? Progressive Corp trades at $217.43 (market cap $126.95B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Progressive Corp is far larger — about 12.6× Twist Bioscience Corp's market cap, and Progressive Corp pays a 0.18% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Twist Bioscience Corp for 27 Days on average.
| PGR | TWST | |
|---|---|---|
Market Cap | $126.95B | $10.08B |
Volume | 2,749,438 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $240.40 | $205.00 |
52-Week Low | $190.40 | $25.45 |
Typical Hold Time | 81 Days | 27 Days |
Enterprise Value | $135.16B | $10.01B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive (PGR) trades at $218.73, up 2.15% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $87.64B and net income of $11.31B, supported by consistent earnings beats and a 12.85% net margin. Analyst consensus sits at $222.23 with 38% buy ratings, while technical indicators show support at $216 and resistance at $221.
PGR presents a favorable risk-reward profile with solid profitability and growth trajectory, though competitive pressures in auto insurance and potential market volatility warrant caution. The stock's current valuation metrics (P/E 10.97, P/S 1.41) appear reasonable relative to earnings power, supporting a constructive outlook for long-term investors.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
